- Home
- BAFN vs KZR Comparison
BAFN vs KZR Comparison
Compare BAFN & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BAFN | KZR |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6M | 44.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BAFN | KZR |
|---|---|---|
| Price | $6.70 | $6.18 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 14.0K | ★ 37.8K |
| Earning Date | 01-29-2026 | 03-24-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,595,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.72 | $3.53 |
| 52 Week High | $19.75 | $6.62 |
Technical Indicators
Market Signals| Indicator | BAFN | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 43.25 |
| Support Level | $6.32 | $6.03 |
| Resistance Level | $7.10 | $6.24 |
| Average True Range (ATR) | 0.39 | 0.12 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 92.02 | 29.63 |
Price Performance
Historical ComparisonAbout BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.